In addition, the diabetes treatments associated with GLP-1 agonism and DPP-4 inhibition have also shown neuroprotective effects in preclinical studies and promising results in reducing major cardiovascular events specifically in type 2 diabetes patients. Here, DPP4 is linked to diabetes mellitus.